Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Salivary glands regenerate after radiation injury through SOX2-mediated secretory cell replacement.

Emmerson E, May AJ, Berthoin L, Cruz-Pacheco N, Nathan S, Mattingly AJ, Chang JL, Ryan WR, Tward AD, Knox SM.

EMBO Mol Med. 2018 Jan 15. pii: e8051. doi: 10.15252/emmm.201708051. [Epub ahead of print]

2.

Aire-deficient mice provide a model of corneal and lacrimal gland neuropathy in Sjögren's syndrome.

Chen FY, Lee A, Ge S, Nathan S, Knox SM, McNamara NA.

PLoS One. 2017 Sep 19;12(9):e0184916. doi: 10.1371/journal.pone.0184916. eCollection 2017.

3.

SOX2 regulates acinar cell development in the salivary gland.

Emmerson E, May AJ, Nathan S, Cruz-Pacheco N, Lizama CO, Maliskova L, Zovein AC, Shen Y, Muench MO, Knox SM.

Elife. 2017 Jun 17;6. pii: e26620. doi: 10.7554/eLife.26620.

4.

Identification and characterization of a rich population of CD34+ mesenchymal stem/stromal cells in human parotid, sublingual and submandibular glands.

Togarrati PP, Sasaki RT, Abdel-Mohsen M, Dinglasan N, Deng X, Desai S, Emmerson E, Yee E, Ryan WR, da Silva MCP, Knox SM, Pillai SK, Muench MO.

Sci Rep. 2017 Jun 14;7(1):3484. doi: 10.1038/s41598-017-03681-1.

5.

Defining epithelial cell dynamics and lineage relationships in the developing lacrimal gland.

Farmer DT, Nathan S, Finley JK, Shengyang Yu K, Emmerson E, Byrnes LE, Sneddon JB, McManus MT, Tward AD, Knox SM.

Development. 2017 Jul 1;144(13):2517-2528. doi: 10.1242/dev.150789. Epub 2017 Jun 2.

6.

miR-205 is a critical regulator of lacrimal gland development.

Farmer DT, Finley JK, Chen FY, Tarifeño-Saldivia E, McNamara NA, Knox SM, McManus MT.

Dev Biol. 2017 Jul 1;427(1):12-20. doi: 10.1016/j.ydbio.2017.05.012. Epub 2017 May 13.

PMID:
28511845
7.

Sensitization patterns among patients with atopic dermatitis evaluated in a large tertiary care pediatric center.

Knox SM, Erwin EA, Mosser-Goldfarb JL, Scherzer R.

Ann Allergy Asthma Immunol. 2017 May;118(5):645-647. doi: 10.1016/j.anai.2017.03.006. Epub 2017 Mar 31. No abstract available.

PMID:
28372896
8.

Operative management of dermatofibrosarcoma protuberans of the breast.

Kinney MH, Knox SM.

Proc (Bayl Univ Med Cent). 2016 Jul;29(3):315-7.

9.

Salivary gland development and disease.

Mattingly A, Finley JK, Knox SM.

Wiley Interdiscip Rev Dev Biol. 2015 Nov-Dec;4(6):573-90. doi: 10.1002/wdev.194. Epub 2015 May 13. Review.

PMID:
25970268
10.

Submandibular parasympathetic gangliogenesis requires sprouty-dependent Wnt signals from epithelial progenitors.

Knosp WM, Knox SM, Lombaert IM, Haddox CL, Patel VN, Hoffman MP.

Dev Cell. 2015 Mar 23;32(6):667-77. doi: 10.1016/j.devcel.2015.01.023.

11.

Manipulating the murine lacrimal gland.

Finley JK, Farmer D, Emmerson E, Cruz Pacheco N, Knox SM.

J Vis Exp. 2014 Nov 18;(93):e51970. doi: 10.3791/51970.

12.

Parasympathetic innervation regulates tubulogenesis in the developing salivary gland.

Nedvetsky PI, Emmerson E, Finley JK, Ettinger A, Cruz-Pacheco N, Prochazka J, Haddox CL, Northrup E, Hodges C, Mostov KE, Hoffman MP, Knox SM.

Dev Cell. 2014 Aug 25;30(4):449-62. doi: 10.1016/j.devcel.2014.06.012.

13.

Parasympathetic stimulation improves epithelial organ regeneration.

Knox SM, Lombaert IM, Haddox CL, Abrams SR, Cotrim A, Wilson AJ, Hoffman MP.

Nat Commun. 2013;4:1494. doi: 10.1038/ncomms2493.

14.

Salivary gland organogenesis.

Knosp WM, Knox SM, Hoffman MP.

Wiley Interdiscip Rev Dev Biol. 2012 Jan-Feb;1(1):69-82. doi: 10.1002/wdev.4. Epub 2011 Nov 17. Review.

PMID:
23801668
15.

Salivary gland progenitor cell biology provides a rationale for therapeutic salivary gland regeneration.

Lombaert IM, Knox SM, Hoffman MP.

Oral Dis. 2011 Jul;17(5):445-9. doi: 10.1111/j.1601-0825.2010.01783.x. Epub 2011 Jan 11. Review.

16.

Parasympathetic innervation maintains epithelial progenitor cells during salivary organogenesis.

Knox SM, Lombaert IM, Reed X, Vitale-Cross L, Gutkind JS, Hoffman MP.

Science. 2010 Sep 24;329(5999):1645-7. doi: 10.1126/science.1192046.

17.

Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan.

Chuang CY, Lord MS, Melrose J, Rees MD, Knox SM, Freeman C, Iozzo RV, Whitelock JM.

Biochemistry. 2010 Jul 6;49(26):5524-32. doi: 10.1021/bi1005199.

18.

Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis.

Patel VN, Knox SM, Likar KM, Lathrop CA, Hossain R, Eftekhari S, Whitelock JM, Elkin M, Vlodavsky I, Hoffman MP.

Development. 2007 Dec;134(23):4177-86. Epub 2007 Oct 24.

19.

Clinical utility of breast magnetic resonance imaging in patients presenting with primary breast cancer.

Dao TN, Lamont JP, Knox SM.

Proc (Bayl Univ Med Cent). 2007 Jul;20(3):227-30.

20.

The function of a Drosophila glypican does not depend entirely on heparan sulfate modification.

Kirkpatrick CA, Knox SM, Staatz WD, Fox B, Lercher DM, Selleck SB.

Dev Biol. 2006 Dec 15;300(2):570-82. Epub 2006 Sep 15.

21.

Perlecan: how does one molecule do so many things?

Knox SM, Whitelock JM.

Cell Mol Life Sci. 2006 Nov;63(21):2435-45. Review.

PMID:
16952056
22.

Multitasking by multivalent circular DNA aptamers.

Di Giusto DA, Knox SM, Lai Y, Tyrelle GD, Aung MT, King GC.

Chembiochem. 2006 Mar;7(3):535-44.

PMID:
16482500
24.

Predictors for nonsentinel node involvement in breast cancer patients with micrometastases in the sentinel lymph node.

Ganaraj A, Kuhn JA, Jones RC, Grant MD, Andrews VR, Knox SM, Netto GJ, Altrabulsi B, Livingston SA, McCarty TM.

Proc (Bayl Univ Med Cent). 2003 Jan;16(1):3-6.

25.

Survival analysis following sentinel lymph node biopsy: a validation trial demonstrating its accuracy in staging early breast cancer.

Carlo JT, Grant MD, Knox SM, Jones RC, Hamilton CS, Livingston SA, Kuhn JA.

Proc (Bayl Univ Med Cent). 2005 Apr;18(2):103-7.

26.

Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection.

Fant JS, Grant MD, Knox SM, Livingston SA, Ridl K, Jones RC, Kuhn JA.

Ann Surg Oncol. 2003 Mar;10(2):126-30.

PMID:
12620906
27.

Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging.

Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, Grant MD, Hampe DW, Savino DA, Harms SE.

Cancer. 1996 Jul 1;78(1):91-100.

28.

Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen.

Cathcart CK, Jones SE, Pumroy CS, Peters GN, Knox SM, Cheek JH.

Breast Cancer Res Treat. 1993 Sep;27(3):277-81.

PMID:
8312586
29.

Fat-suppressed three-dimensional MR imaging of the breast.

Harms SE, Flamig DP, Hesley KL, Evans WP 3rd, Cheek JH, Peters GN, Knox SM, Savino DA, Netto GJ, Wells RB, et al.

Radiographics. 1993 Mar;13(2):247-67.

PMID:
8460218
30.
31.
32.

Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer.

Jones SE, Mennel RG, Peters GN, Westrick MA, Brooks BD, Knox SM, McGuffey P.

Invest New Drugs. 1988 Sep;6(3):195-8.

PMID:
2847991

Supplemental Content

Support Center